Applied Dna Sciences INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
BNB Plus Corp. has entered into a Settlement Agreement to terminate its Digital Services and Strategic Advisor Agreements with Cypress LLC and Cypress Management LLC, involving a $1 million payment and issuance of preferred stock.
BNB Plus Corp. announced its common stock will be delisted from Nasdaq effective July 14, 2026, due to non-compliance with the minimum bid price requirement, and will transition to trading on the OTCQB Venture Market.
BNB Plus Corp. has amended its Registration Rights Agreement, extending the filing date for registration statements related to its registrable securities.
BNB Plus Corp. has closed additional warrant inducement agreements, bringing total anticipated gross proceeds from its recent financing initiatives to $4.3 million.
BNB Plus Corp. announced initial commitments of $4.1 million in convertible preferred stock financing, with a target of $5 million, to support a strategic review of its digital asset and biotechnology businesses.
BNB Plus Corp. received a delisting notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement and is ineligible for a compliance period due to prior reverse stock splits.
BNB Plus Corp. strengthens its board with the appointment of James Haft, a digital asset and DeFi expert, to support its strategic growth in blockchain and BNB treasury operations.
BNB Plus Corp. announced the resignation of director Elizabeth M. Schmalz Shaheen, effective January 15, 2026, with no reported disagreements.
BNB Plus Corp. stockholders approved key proposals including increasing authorized common stock to 500 million shares and the exercisability of warrants at a special meeting on December 12, 2025.
Applied DNA Sciences, Inc. rebrands as BNB Plus Corp. and appoints Josh Kruger as Chairman, signaling a strategic pivot to a yield-optimized, BNB-based digital asset treasury strategy.
Applied DNA Sciences announced the appointment of Joshua Kruger as its new Chairman and director, who is not independent under Nasdaq rules and has significant ties to the company's strategic advisors.
Applied DNA Sciences, Inc. has entered into an At The Market Offering Agreement to sell up to $8.15 million of common stock and appointed Patrick Horsman as Chief Investment Officer for its digital asset strategy.
Applied DNA Sciences successfully closed a private placement raising $27 million and launched a new yield-focused BNB digital asset treasury strategy.
Applied DNA Sciences announced a significant workforce reduction and a strategic pivot to a BNB-focused digital asset treasury strategy, alongside a ticker symbol change to BNBX.
Applied DNA Sciences announced a private placement of up to $58 million to fund a new BNB-focused digital asset treasury strategy, alongside significant management changes.
Applied DNA Sciences announced a $26.8 million private placement to fund a new BNB-focused digital asset treasury strategy, alongside significant management changes.
Applied DNA Sciences reported third quarter fiscal 2025 financial results, highlighting a strategic shift to pure-play synthetic DNA and mRNA manufacturing solutions and reduced cash burn.
Applied DNA Sciences, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing and the cancellation of a previously scheduled delisting hearing.
8-K: Applied DNA Sciences Pivots to Core Synthetic DNA Business, Implements Significant Cost Reductions
Applied DNA Sciences announced a strategic restructuring, ceasing operations at Applied DNA Clinical Labs and reducing its workforce by 27% to exclusively focus on its LineaRx synthetic DNA manufacturing business.
Applied DNA Sciences, Inc. announced the retirement of long-serving CEO Dr. James A. Hayward and the immediate appointment of President and COO Judy Murrah as his successor, effective June 18, 2025.
Applied DNA Sciences, Inc. received a delisting notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement and has requested a hearing to appeal the decision, which stays immediate delisting.
Applied DNA Sciences, Inc. will implement a 1-for-15 reverse stock split effective June 2, 2025, primarily to regain compliance with Nasdaq's minimum bid price requirement.
Applied DNA Sciences successfully held its 2025 annual meeting, electing directors, ratifying the accounting firm, and approving a potential reverse stock split, among other proposals.
Applied DNA Sciences' LineaRx segment drives revenue growth with a 44% increase year-over-year, contributing to a 6% overall revenue increase for the second quarter of fiscal 2025.
Applied DNA Sciences has received notification from Nasdaq that it has regained compliance with the minimum bid price rule, ensuring continued listing on the Nasdaq Capital Market.
Applied DNA Sciences announces the date for its 2025 Annual Meeting of Stockholders and provides deadlines for shareholder proposals and director nominations.
Applied DNA Sciences will implement a 1-for-50 reverse stock split, effective March 14, 2025, to meet Nasdaq's minimum bid price requirement.
Applied DNA Sciences' special meeting of stockholders was reconvened on February 28, 2025, but failed to achieve a quorum, delaying the approval of warrant exercises related to a previous offering.
Applied DNA Sciences adjourns its special meeting for a second time due to insufficient stockholder representation to reach a quorum, delaying a vote on warrant holder approval.
Applied DNA Sciences reports a 34% increase in total revenues for Q1 2025, alongside strategic restructuring including exiting the DNA Tagging business and a 20% workforce reduction.